tbuckley/cabot-search huggingface dataset:
1395 THE REDUCTION IN LIVER VOLUME IN POLYCYSTIC LIVER DISEASE WITH LANREOTIDE IS DOSE DEPENDENT AND IS MOST PRONOUNCED IN PATIENTS WITH THE HIGHEST LIVER VOLUME
Authors: F. Temmerman, R. Vanslembrouck, W. Coudyzer, B. Bammens, W. Laleman, D. Cassiman, S. van der Merwe, C. Verslype, W. Van Steenbergen, J. van Pelt, Y. Pirson, J. Drenth, F. Nevens
Journal: Journal of Hepatology (2012)
P-117 Sarcopenia at First Diagnosis Predicts a Reduced Survival in Patients Affected by Hepatocarcinoma
Authors: P. Begini, E. Gigante, G. Antonelli, F. Carbonetti, E. Iannicelli, G. Anania, A. Pellicelli, G. Delle Fave, M. Marignani
Journal: Annals of Oncology (2015)
AT-23 * A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: A CERN CLINICAL TRIAL
Authors: M. Gilbert, Y. Yuan, K. Wani, J. Wu, A. Omuro, F. Lieberman, H. I. Robins, E. Gerstner, J. Wu, P. Wen, T. Mikkelsen, T. Armstrong, K. Aldape
Journal: Neuro-Oncology (2014)

BACKGROUND: Ependymoma is an uncommon adult primary CNS tumor. Initial treatment includes extensive resection often followed by but there is no standard treatment for recurrent disease. Molecular studies show most tumors have ErbB2 overexpression and unmethylated MGMT promoter status. We developed a clinical trial combining lapatinib(targets ErbB1, ErbB2) with dose-dense temozolomide. METHODS: Eligibility criteria included adults(≥18), KPS ≥ 70, with centrally confirmed ependymoma (grades I, II, or III). Treatment plan: TMZ(125mg-150mg/m2/d, 7on/7off) plus lapatinib(1250 mg po/qd) continuous dosing. Cycle = 4wks; imaging and patient reported outcomes measures(PRO:MDASI-BT/MDASI-Spine) every 2 cycles, maximum 24 cycles. The primary endpoint was median progression free survival(PFS); secondary objectives: 6-month PFS, 12-month PFS, response rate, overall survival, and change in symptom burden. A Bayesian design sequentially monitored treatment efficacy based on posterior probabilities. RESULTS: Fifty patients enrolled. Median age 47(20-81), women = 28(56%), median KPS = 90. Tumor grade: anaplastic (III) = 18; ependymoma (II) = 24; myxopapillary(I) = 8. Tumor location: supratentorial (ST) = 14; infratentorial(IT) = 5; spinal cord(SC) = 25; multifocal (MF) = 6. Median PFS: overall = 36 wks. By grade: I = 96 wks; II = 45 wks; III= 25.3 wks. By location: ST = 24 wks; IT = 21 wks; SC= 96 wks. PFS rates(6-month,12-month): Grade I(88%,75%), Grade II(63%,46%), Grade III(50%,28%); ST(43%,29%), IT(40%,20%), SC(80%,64%), MF(50%,17%). Best response: CR = 1(Gr III), PR = 4(Gr II = 2,III = 1), SD = 33, PD = 12. Treatment was well tolerated with only modest myelotoxicity and rash. No cardiotoxity. All patients completed the MDASI-BT/SP(reported separately). Preliminary gene expression analysis (23 tumors) correlated response with higher ErbB2 mRNA expression(p = .03). CONCLUSION: Daily lapatinib with dose-dense TMZ was well tolerated and demonstrated activity in the spectrum of ependymoma defined by location and tumor grade. Ongoing molecular profiling will determine whether there is a potential predictive marker for response, given the preliminary correlation of response with ErbB2 expression. This is the first prospective clinical trial in adult ependymoma and demonstrates feasibility of accrual, tumor and PRO collection and efficacy with a possible predictive marker requiring validation in a subsequent clinical trial.
The Frequency of Familial Dilated Cardiomyopathy in a Series of Patients with Idiopathic Dilated Cardiomyopathy
Authors: Virginia V. Michels, Patricia P. Moll, Fletcher A. Miller, A. Jamil Tajik, Julia S. Chu, David J. Driscoll, John C. Burnett, Richard J. Rodeheffer, James H. Chesebro, Henry D. Tazelaar
Journal: New England Journal of Medicine (1992)

Dilated cardiomyopathy is characterized by an increase in ventricular size and impairment of ventricular function. Most cases are believed to be sporadic, and familial dilated cardiomyopathy is usually considered to be a rare and distinct disorder. We studied the proportion of cases of idiopathic dilated cardiomyopathy that were familial in a large sequential series of patients whose first-degree relatives were investigated regardless of whether these relatives had cardiac symptoms.
Detection of SARS Coronavirus in Plasma by Real-Time RT-PCR
Authors: Paul R. Grant, Jeremy A. Garson, Richard S. Tedder, Paul K.S. Chan, John S. Tam, Joseph J.Y. Sung
Journal: New England Journal of Medicine (2003)

To the Editor: The identification and sequencing of a novel coronavirus1 associated with the recently described severe acute respiratory syndrome (SARS)2 have permitted the development of antibody-...
An Interferon-free Antiviral Regimen for HCV after Liver Transplantation
Authors: Paul Y. Kwo, Parvez S. Mantry, Eoin Coakley, Helen S. Te, Hugo E. Vargas, Robert Brown, Fredric Gordon, Josh Levitsky, Norah A. Terrault, James R. Burton, Wangang Xie, Carolyn Setze, Prajakta Badri, Tami Pilot-Matias, Regis A. Vilchez, Xavier Forns
Journal: New England Journal of Medicine (2014)

Hepatitis C virus (HCV) infection is the leading indication for liver transplantation worldwide, and interferon-containing regimens are associated with low response rates owing to treatment-limiting toxic effects in immunosuppressed liver-transplant recipients. We evaluated the interferon-free regimen of the NS5A inhibitor ombitasvir coformulated with the ritonavir-boosted protease inhibitor ABT-450 (ABT-450/r), the nonnucleoside NS5B polymerase inhibitor dasabuvir, and ribavirin in liver-transplant recipients with recurrent HCV genotype 1 infection.We enrolled 34 liver-transplant recipients with no fibrosis or mild fibrosis, who received ombitasvir-ABT-450/r (at a once-daily dose of 25 mg of ombitasvir, 150 mg of ABT-450, and 100 mg of ritonavir), dasabuvir (250 mg twice daily), and ribavirin for 24 weeks. Selection of the initial ribavirin dose and subsequent dose modifications for anemia were at the investigator's discretion. The primary efficacy end point was a sustained virologic response 12 weeks after the end of treatment.Of the 34 study participants, 33 had a sustained virologic response at post-treatment weeks 12 and 24, for a rate of 97% (95% confidence interval, 85 to 100). The most common adverse events were fatigue, headache, and cough. Five patients (15%) required erythropoietin; no patient required blood transfusion. One patient discontinued the study drugs owing to adverse events after week 18 but had a sustained virologic response. Blood levels of calcineurin inhibitors were monitored, and dosages were modified to maintain therapeutic levels; no episode of graft rejection was observed during the study.Treatment with the multitargeted regimen of ombitasvir-ABT-450/r and dasabuvir with ribavirin was associated with a low rate of serious adverse events and a high rate of sustained virologic response among liver-transplant recipients with recurrent HCV genotype 1 infection, a historically difficult-to-treat population. (Funded by AbbVie; CORAL-I ClinicalTrials.gov number, NCT01782495.).
O2.05 * MAY WE ROUTINELY SPARE HIPPOCAMPAL REGION IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA DURING WHOLE BRAIN RADIOTHERAPY?
Authors: B. Diletto, D. Marchesano, S. Chiesa, A. Alitto, S. Gaudino, M. Ferro, C. Mazzarella, C. Colosimo, V. Valentini, M. Balducci
Journal: Neuro-Oncology (2014)

PURPOSE: The neurocognitive decline is one of the main limiting factor of whole brain irradiation. This study evaluate the correlation between the site of (Primary Central Nervous System Lymphoma) PCNSL lesions and the hippocampal region in order to explore the feasibility of routinely sparing of the hippocampus during whole-brain radiotherapy (WBRT) to prevent radiation-induced neurocognitive decline. METHODS AND MATERIALS: Patients (>18 years, ECOG <4) with pathologically proven PCNSL and MRI image pre-treatment were retrospectively reviewed. All patients had received high-dose of methotrexate (HD-MTX) before WBRT. T1-weighted, post-contrast axial MR image sets obtained prior to cranial irradiation were imported on Varian Eclipse treatment planning system, version 11 (Varian Medical Systems) and registered with the simulation CT. The hippocampus as well as each PCNSL lesions were contoured. Three dimensional envelopes surrounding the hippocampus were generated adding 5, 10, and 15 mm and the distance of brain lesions were recorded as <5 mm, 5 to <10 mm, 10 to <15 mm, and >15 mm from the hippocampus. The minimum margin of 5 mm was taken account for systematic setup error and dose fall-off between whole brain clinical target volume and the hippocampus. RESULTS: Between 2006 and 2013, 23 patients were treated and 17 pts with 35 lesions were eligible for this study. In this sample PCNSL lesions were positioned: parietal lobe (28,6%), deep brain structures (20%), frontal lobe (17,1%), temporal lobe (14,3%), brainstem (8,6%), other sites (11,4%). Six patients were affected by multiple lesions. In 7/17 patients (41.2%) PCNSL lesion was distant from the hippocampus region less than 5 mm. Eight out 35 lesion (22.8%) were localized within 5 mm of hippocampal region, three of them involved the hippocampus. Over 15 mm of the hippocampus we observed 51,4% (n = 18) of brain lesions, while 11,4% (n = 4) and 14.4% (n = 5) were between 10-15 mm. CONCLUSIONS: These data show that routinely sparing of the hippocampus region is not recommended; it must be considered when the spatial distribution of PCNSL is more than 5 mm.
1306 METABOLIC SYNDROME AND SUROGATE MARKERS OF INSULIN RESISTANCE IN NONALCOHOLIC FETTY LIVER DISEASE (NAFLD), CHRONIC HEPATITIS C (CHC) AND B (CHB) IN BULGARIA
Authors: C. Marinova, A. Alexiev, K. Antonov, D. Jelev, L. Mateva, R. Ivanova
Journal: Journal of Hepatology (2012)
Aggressive Lipid-Lowering Therapy Compared with Angioplasty in Stable Coronary Artery Disease
Authors: Bertram Pitt, David Waters, William Virgil Brown, Ad J. van Boven, Leonard Schwartz, Lawrence M. Title, Daniel Eisenberg, Linda Shurzinske, Lisa S. McCormick
Journal: New England Journal of Medicine (1999)

Percutaneous coronary revascularization is widely used in improving symptoms and exercise performance in patients with ischemic heart disease and stable angina pectoris. In this study, we compared percutaneous coronary revascularization with lipid-lowering treatment for reducing the incidence of ischemic events.
WITHDRAWAL OF MAINTAINENCE INFLIXIMAB THERAPY
Authors: L Lee, J Boyd, S Lanzon-Miller
Journal: Gut (2013)

Aims/Background Infliximab (IFX) is a chimeric monoclonal antibody effective for inducing and maintaining remission in Crohn's disease (CD) and ulcerative colitis (UC). Long term therapy is efficacious for maintaining clinical remission; however, infliximab-use is associated with significant side effects and considerable costs. NICE recommends that patients be assessed for cessation of therapy on a yearly basis. This audit analyses our ability to withdrawal infliximab for patients established on maintenance therapy. Method A retrospective cohort study of patients with CD and UC on infliximab at Milton Keynes General hospital were included in this study. Patients were identified from the infliximab database and the medical records were reviewed. The duration of infliximab therapy was recorded along with the ability to withdraw therapy at yearly review. Results Forty-five patients were included for analysis of which 58% were male. The median age was 36.6 years. The majority of patients had a diagnosis of Crohn's disease (42/45). The mean follow up period of patients was 1.6 years (range 0–4 years). Mucosal healing was noted in 33.3% of patients. Six patients were able to stop Infliximab therapy of which 66.6% were stopped within the first two years of therapy. None of these patients required repeat infliximab therapy. There was no correlation between disease duration/age of patient or disease location in our ability to stop infliximab therapy. Conclusion Infliximab is very successful at inducing mucosal healing and inducing clinical remission. When patients were assessed at year 1, the vast majority were not able to stop infliximab due to poor symptom control or ongoing endoscopic disease. Significantly more patients were able to stop therapy by the second year of therapy. We conclude, that from our experience, the ideal point to consider stopping infliximab therapy is within the first two years of therapy and this correlates very well with the soon to be published European consensus recommendations (EPACT-2).
Identification of PLZF as an osteochondrogenic transcription factor in mesenchymal stem cells
Authors: F Djouad, D Guérit, C Bony, C Jorgensen, D Noël
Journal: Annals of the Rheumatic Diseases (2012)

Mesenchymal stem cells (MSC) are suitable sources for cell-based therapies in cartilage engineering. However, their potential to regenerate a fully functional tissue relies on the presence of a differentiation factor. The identification of such a specific factor represents the major issue of this study. Bone marrow-derived human MSC were induced to differentiate towards chondrocytes using the micropellet culture technique in presence of chondrogenic medium containing hBMP-2 for 21 days. Total RNA were hybridised on DNA microarrays (Affymetrix U133A). Quantitative RT-PCR was performed on RNA extracted at various time points during chondrogenesis. The C3H10T1/2 murine MSC line was stably transfected with a plasmid expressing PLZFand cultured in chondro-, osteo-, adipogenic conditions. Among the 1354 differentially regulated genes during chondrogenesis, 705 genes were up regulated in MSC-derived chondrocytes. The authors first focused our attention on transcription factors and in particular, on PLZF which was shown to be significantly increased compared to undifferentiated MSC using real time PCR, as soon as day 2 of chondrogenesis. The authors thus derived stable clones of C3H10T1/2 cells over-expressing PLZF (C3-PLZF). After 21 days of culture in micropellet in presence of tumour growth factor-β3, the authors could observe a significantly higher level of aggrecan, collagen IIB and the downregulation of collagen I in C3-PLZF compared to naïve MSC. In parallel, the authors demonstrated that PLZF over-expression increased, in a dose-dependent manner, the expression level of Sox9, the master chondrogenic regulator. Moreover, the engineered cells show a higher osteogenic potential than naïve C3H10T1/2 cells while displaying a lower adipogenic potential when cultured in specific inducing conditions. Our results suggest that PLZF is one essential transcription factor involved in the early steps of chondrogenesis acting upstream of Sox9. Further studies will aim at determining the mechanism underlining the activation of chondrocyte-specific markers.
COMPARISON OF CARDIOVASCULAR EVENTS BETWEEN PATIENTS ACHIEVING LOW-DENSITY LIPOPROTEIN PARTICLE TARGETS AND PATIENTS ACHIEVING LOW-DENSITY LIPOPROTEIN CHOLESTEROL TARGETS IN A MIXED PRIMARY/SECONDARY PREVENTION SAMPLE
Authors: Peter P. Toth, Michael Grabner, Rajeshwari Punekar, Ralph Quimbo, Mark Cziraky, Ray Pourfarzib, William Cromwell, Deborah Winegar, Terry Jacobson
Journal: Journal of the American College of Cardiology (2015)
CORRELATION OF CORONARY ARTERY CALCIUM SCORING ON UNGATED COMPUTED TOMOGRAPHY COMPARED TO GATED CARDIAC COMPUTED TOMOGRAPHY SCANS FROM THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS
Authors: Lily Honoris, Anthony DeFranco, Steven Port, Chi Cho, Dong Li, Khurram Nasir, Richard Kronmal, R. Graham Barr, Matthew Budoff
Journal: Journal of the American College of Cardiology (2015)
Abstract 1768: Comprehensive mass spectrometry based metabolomic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer
Authors: Shiro Urayama, Wei Zou, Vladimir Tolstikov
Journal: Cancer Research (2010)

Abstract Background: Poor outcome of pancreatic cancer (PDAC) necessitates development of early diagnostic method to reduce mortality. In current study, metabolic profiling of plasma samples from selected cancer patients and noncancerous controls was performed to seek novel metabolic biomarkers of PDAC. Comprehensive mass spectrometry based analytical platform were applied for detection of compounds in the plasma from early stage PDAC patients. Methods: Plasma available from the patients involved in the IRB-approved UC Davis Pancreas Registry was utilized. Five histologically proven cases of early stage pancreatic cancer without clinical evidence of distant metastasis [AJCC TNM stages: IB (2) and IIB (3)] and 5 noncancerous cases [3 chronic pancreatitis, 2 normal-based on clinical and follow-up evidences] were chosen from the Registry. Combination mass spectrometry (MS) methods, GC-TOF-, HILIC-LC-ESI-, and RP-LC-ESI-MS were applied for the plasma analysis. Data values obtained were evaluated for principle component analysis (PCA). Further feature selection and ANOVA were conducted after the PCA. Statistical significance was defined as p-value less than 0.05. Feature components with statistically significant classifiers of the PDAC were analyzed further with LTQ-Orbitrap MS for accurate mass measurement. Mass spectra of potential biomarkers thus obtained were spectrally corrected and unique elemental formula was searched against CAS database using the strategy of Explore Substances-Chemical Structure for known compounds. Mass Frontier 5.0 was used for MS/MS fragmentation modeling analysis; with parent compounds that had the best match of MS/MS fragmentation pattern were considered as the molecular structure of the potential biomarkers. Results: The candidate biomarkers included amino acids (N-methylalanine, lysine, glutamine, phenylalanine), fatty acids (arachidonic acid), lipids (lysoPC (18:2), PC (34:2), PE (26:0)), and bile acids (tauroursodeoxycholic and taurocholic acids, deoxycholylglycine, cholylglycine). Conclusion: We have demonstrated that combination of the comprehensive mass spectrometry based metabolic profiling techniques, data mining, and data analysis successfully find potent classifiers for pancreatic cancer in plasma. These metabolites upon validation, selectivity study, and broader cohort study could become clinical biomarkers for early diagnosis of pancreatic cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1768.
Abstract 4985: Expression of FasL on the tumor endothelium establishes a selective immune barrier in ovarian cancer.
Authors: Greg Motz, George Coukos
Journal: Cancer Research (2013)

Abstract There is an intimate relationship between angiogenesis and immune suppression in cancer, and anti-angiogenesis strategies can complement cancer immunotherapy. Previous research has implicated the tumor endothelium as a critical regulator of anti-tumor immunity, and our current work establishes a new role for the tumor endothelium as a critical barrier to T cell infiltration mediated through FasL. FasL is an important regulator of immunity and apoptosis, and we have found that, in contrast to the endothelium of normal tissues, the endothelium of multiple tumor types expressed FasL. FasL expression was restricted to tumor islets, and hypoxic tumor cell-conditioned media induced FasL on endothelial cells in vitro. Combination treatment with proangiogenic growth factors VEGF and PGE2 induced endothelial FasL expression in vitro, and COX1 and VEGF expression were associated with endothelial expression of FasL in ovarian cancer patients. Combinatorial blockade of VEGF and COX enzymes reduced endothelial FasL expression in mice, decreased tumor volume, and increased the CD8/FoxP3 ratio. In patients, low endothelial FasL expression was associated with a high CD8/Foxp3 ratio and increased survival. We found that endothelial FasL contributes to an unfavorable CD8/FoxP3 ratio through preferential killing of tumor-reactive CD8 T cells relative to Tregs. Increased intratumoral CD8/FoxP3 ratio was also observed in tumors grown on gld and lpr mice, but tumor growth was not robustly inhibited in these mice. Tumor control was dependent on the induction of an anti-tumor immune response, and CD8 depletion reversed the effects of VEGF and COX blockade. Additionally, combinatorial VEGF and COX blockade, tumors grown on gld mice, or the use of anti-FasL antibody all enhanced infiltration of adoptively transferred anti-tumor T cells and reduced apoptosis of transferred cells. Together, this work lends mechanistic insights into existing observations regarding T cells and tumor angiogenesis, and provides additional evidence for the paradigm that angiogenesis and immune suppression are intricately linked. Additionally, this work provides new strategies for cancer immunotherapy that may result in superior tumor control in patients. Citation Format: Greg Motz, George Coukos. Expression of FasL on the tumor endothelium establishes a selective immune barrier in ovarian cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4985. doi:10.1158/1538-7445.AM2013-4985 Note: This abstract was not presented at the AACR Annual Meeting 2013 because the presenter was unable to attend.
The Women's Leadership Summit On Mammography Held at the U.S. Capitol
Authors: C. K. Wittenberg
Journal: JNCI Journal of the National Cancer Institute (1989)

Journal Article The Women's Leadership Summit On Mammography Held at the U.S. Capitol Get access Clarissa K. Wittenberg Clarissa K. Wittenberg Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 20, 18 October 1989, Pages 1535–1537, https://doi.org/10.1093/jnci/81.20.1535 Published: 18 October 1989
Preparing for a Consumer-Driven Genomic Age
Authors: James P. Evans, David C. Dale, Cathy Fomous
Journal: New England Journal of Medicine (2010)

Advances in genomic technologies permit the simultaneous analysis of millions of variants across the genome and may soon allow for meaningful estimation of one's risks of developing cancer, diabetes, and other common diseases. These advances are converging with the movement toward consumer-driven health care and patient empowerment. Whereas in the past, medical testing was firmly under the control of medical practitioners, genomic information is now increasingly available outside traditional medical settings. Patients are no longer subordinate, passive recipients of physician-initiated genetic testing; rather, patients can instigate their own testing and often know more than their clinicians about particular genetic topics. . . .